Lionel Sharon Anbumalar, Selvarajan Sushil, Korula Anu, Kulkarni Uday, Devasia Anup, Abubacker Fouzia N, Abraham Aby, Mathews Vikram, Lakshmi Kavitha M, George Biju
Department of Haematology, Christian Medical College, Vellore, Tamil Nadu India.
Indian J Hematol Blood Transfus. 2023 Jul;39(3):419-428. doi: 10.1007/s12288-022-01597-z. Epub 2022 Dec 18.
Immunosuppressive therapy (IST) with anti-thymocyte globulin (ATG) and Cyclosporine (CSA) in aplastic anaemia (AA) results in improvement of blood counts between 3 and 6 months for the majority of patients. Infection is the most lethal complication in aplastic anemia and may arise due to several factors. We performed this study to determine the prevalence and predictors of specific infection types before and after IST. Six hundred and seventy-seven (546 adults; 434 males) transplant ineligible patients received ATG and CSA between 1995 and 2017. All patients who were transplant ineligible and received IST in this period were included. Infections before IST was seen in 209 (30.9%) and in 430 (63.5%) patients post IST. There were 700 infective episodes in the six months post-IST, including 216 bacterial, 78 fungal, 33 viral, and 373 culture-negative febrile episodes. Infections were highest (98, 77.8%) in very severe aplastic anaemia as compared to Severe AA (SAA) and Non-Severe AA (NSAA) ( < 0.001). Infections were also significantly higher in those who did not respond to ATG (71.1% vs. 56.8%, = 0.003). At six months post-IST were 545 (80.5%) alive, and there were 54 (7.9%) deaths due to infection. Significant predictors of mortality were paediatric AA, very severe aplastic anaemia, pre or post ATG infections, and lack of response to ATG. Mortality was highest in those with combined bacterial and fungal infections post IST ( < 0.001). We conclude that infections are a common complication (63.5%) of IST. Mortality was highest when both bacterial and fungal infections were present. Routine use of growth factors and prophylactic antifungal and antibacterial agents was not part of our protocol, despite which 80.5% of the cohort was alive at the end of six months.
在再生障碍性贫血(AA)中,使用抗胸腺细胞球蛋白(ATG)和环孢素(CSA)进行免疫抑制治疗(IST)可使大多数患者在3至6个月内血细胞计数得到改善。感染是再生障碍性贫血最致命的并发症,可能由多种因素引起。我们进行这项研究以确定IST前后特定感染类型的患病率和预测因素。1995年至2017年间,677例(546例成人;434例男性)不适合移植的患者接受了ATG和CSA治疗。纳入了在此期间所有不适合移植且接受IST的患者。IST前有209例(30.9%)患者发生感染,IST后有430例(63.5%)患者发生感染。IST后六个月有700次感染发作,包括216次细菌感染、78次真菌感染、33次病毒感染和373次培养阴性的发热发作。与重度再生障碍性贫血(SAA)和非重度再生障碍性贫血(NSAA)相比,极重度再生障碍性贫血患者的感染率最高(98例,77.8%)(P<0.001)。对ATG无反应的患者感染率也显著更高(71.1%对56.8%,P=0.003)。IST后六个月时,545例(80.5%)患者存活,54例(7.9%)患者死于感染。死亡的显著预测因素为儿童AA、极重度再生障碍性贫血、ATG治疗前或治疗后感染以及对ATG无反应。IST后合并细菌和真菌感染的患者死亡率最高(P<0.001)。我们得出结论,感染是IST常见的并发症(63.5%)。当同时存在细菌和真菌感染时死亡率最高。尽管我们的方案中未常规使用生长因子以及预防性抗真菌和抗菌药物,但六个月结束时仍有80.5%的队列患者存活。